Authors: ZORN U DUENSING S LANGKOPF F ANASTASSIOU G KIRCHNER H HADAM M KNUVERHOPF J ATZPODIEN J

Citation: U. Zorn et al., ACTIVE SPECIFIC IMMUNOTHERAPY OF RENAL-CELL CARCINOMA - CELLULAR AND HUMORAL IMMUNE-RESPONSES, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(3), 1997, pp. 157-165

Authors: HASS R MEINHARDT G HADAM M BARTELS H

Citation: R. Hass et al., CHARACTERIZATION OF HUMAN TUR LEUKEMIA-CELLS - CONTINUED CELL-CYCLE PROGRESSION IN THE PRESENCE OF PHORBOL ESTER IS ASSOCIATED WITH RESISTANCE TO APOPTOSIS, European journal of cell biology, 65(2), 1994, pp. 408-416

Authors: BALLMAIER M BOGENBERGER J SHUTTER J WELCHER A TIDOW N KONIG A WILKEN A VONSCHWEINITZ D HADAM M WELTE K

Citation: M. Ballmaier et al., ANALYSIS OF EXPRESSION OF MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTORMESSENGER-RNA IN VARIOUS HUMAN NORMAL AND MALIGNANT-TISSUES, Blood, 84(10), 1994, pp. 10000241-10000241

Authors: MENZEL T SCHOMBURG A KORFER A HADAM M MEFFERT M DALLMANN I CASPER S KIRCHNER H POLIWODA H ATZPODIEN J

Citation: T. Menzel et al., CLINICAL AND PRECLINICAL EVALUATION OF RECOMBINANT PEG-IL-2 IN HUMAN, Cancer biotherapy, 8(3), 1993, pp. 199-212

Authors: ATZPODIEN J KIRCHNER H KORFER A HADAM M SCHOMBURG A MENZEL T DECKERT M FRANZKE A VOLKENANDT M DALLMANN I GROSSE J POLIWODA H

Citation: J. Atzpodien et al., EXPANSION OF PERIPHERAL-BLOOD NATURAL-KILLER-CELLS CORRELATES WITH CLINICAL OUTCOME IN CANCER-PATIENTS RECEIVING RECOMBINANT SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA(2), Tumor biology, 14(6), 1993, pp. 354-359

Authors: SCHNEEKLOTH C KORFER A HADAM M HANNINEN EL MENZEL T SCHOMBURG A DALLMANN I KIRCHNER H POLIWODA H ATZPODIEN J

Citation: C. Schneekloth et al., LOW-DOSE INTERLEUKIN-2 IN COMBINATION WITH INTERFERON-ALPHA EFFECTIVELY MODULATES BIOLOGICAL RESPONSE INVIVO, Acta haematologica, 89(1), 1993, pp. 13-21